Firmonertinib Shows Promise for Rare Lung Cancer Mutation

Patients with specific EGFR lung cancer mutations may see improved response rates with this targeted therapy.

Updated on Oct. 21, 2026 in Cancer

Firmonertinib Shows Promise for Rare Lung Cancer Mutation

Live Poll

Do you believe targeting specific genetic mutations in cancer treatment will improve overall survival rates?

A recent Phase Ib study suggests that the drug firmonertinib shows promise in treating metastatic non-small cell lung cancer (NSCLC) harboring rare PACC mutations. The results offer potential new options for patients with these specific genetic alterations.

Why it matters

PACC mutations compress the ATP-binding pocket of the EGFR protein, which often limits the effectiveness of conventional tyrosine kinase inhibitor (TKI) therapies. This study highlights a targeted approach that may overcome these structural barriers to improve patient outcomes.

This Phase Ib trial evaluated firmonertinib in 47 patients with metastatic EGFR PACC-mutant NSCLC over a 16.5-month follow-up period. The higher 240 mg dose achieved a 68% objective response rate compared to 43% in the 160 mg cohort, though these findings are preliminary.

The players

The University of Texas MD Anderson Cancer Center

A leading academic institution known for cancer research and clinical trials that provided the research leadership for this study.

The details

Firmonertinib is designed with a specific trifluoroethoxy side chain that creates additional contact points within the kinase domain of mutated EGFR proteins. This allows the drug to effectively bind to PACC-mutated receptors that are typically resistant to standard inhibitors. In the study, 80% of patients showed complete molecular response based on plasma ctDNA clearance, with diarrhea reported as the most common adverse event.

2021: Researchers established a classification framework for EGFR mutations.
October 2026: Study results were reported.
Study follow-up period: Patients were tracked for 16.5 months.

Health Landscape

Precision oncology currently struggles to address PACC mutations, which represent 12% of total EGFR mutations. This study marks a shift toward targeted therapies designed to bypass structural resistance, following the pattern of the upcoming Phase III ALPACCA trial.

Patients with NSCLC who are aware of their EGFR mutation status may want to discuss the significance of PACC mutations with their oncologist. As research into targeted inhibitors evolves, it is important to consult a physician regarding whether clinical trial enrollment is appropriate.

The takeaway

Firmonertinib shows potential for treating challenging EGFR PACC mutations in lung cancer patients. Patients and their families should keep track of their specific genetic markers and talk to their care team about how emerging targeted trials might fit into their broader treatment plan.